Heidi Wiehler

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients

Ulrich R. Hengge, Manfred Goos, Vanessa Exner et al. · AIDS · 1998 · 87 citations

Life Sciences, Immunology, Pharmacology +16

Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting

Ulrich R. Hengge, Kristin Stocks, Heidi Wiehler et al. · AIDS · 2003 · 57 citations

Medicine, Endocrinology, Pharmacology +17

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

José M. Gatell, Lambert Assoumou, Graeme Moyle et al. · Clinical Infectious Diseases · 2018 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Ana Gonzalez‐Cordón, Lambert Assoumou, Graeme Moyle et al. · Journal of Antimicrobial Chemotherapy · 2021 · 27 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women.

Ulrich R. Hengge, Kristin Stocks, Sandy Faulkner et al. · PubMed · 2003 · 20 citations

Medicine, Endocrinology, Pharmacology +17